Introduction
From 1 January 2022 to 4 September 2022, a total of 52 996 laboratory-confirmed cases of mpox has been identified globally [1]. The World Health Organization (WHO) declared the Public Health Emergency of International Concern on 23 July 2022. Mpox virus belongs to the Orthopoxvirus genus and has been first detected as a human pathogen in the Zaire (currently known as the Democratic Republic of the Congo, DRC) in 1970. Recently detected endemic regions include; Cameroon, Central African Republic, DRC, Nigeria, Republic of the Congo [2, Reference Bunge3]. Transmission to human occurs through close contact with an infected animal or person or a contaminated material. Animal hosts include a variety of rodents and non-human primates, yet the exact reservoir of mpox is yet to be determined [4, Reference McCollum and Damon5]. To present, mpox has not been considered to be contagious prior to symptom onset, while several case reports identifying asymptomatic infection raise concerns for the feasibility of controlling the multi-country outbreak [Reference De Baetselier6]. Moreover, since the mean incubation period is estimated at 8.5 days and can be up to around 21 days, incidental importation can easily occur [Reference McCollum and Damon5, Reference Grant, Nguyen and Breban7, Reference Miura8].
The risk of mpox has been continuously debated after the eradication of smallpox [Reference Bunge3, Reference Breman and Henderson9]. Despite knowledge of smallpox vaccination being effective against mpox, local and global smallpox eradication by 1980 lead to cessation of routine vaccination, and especially cohorts born post smallpox eradication is presumed to have no immunity against mpox [Reference Grant, Nguyen and Breban7, Reference Breman and Henderson9]. Therefore, increased susceptibility to mpox infection especially among younger generations which were born after smallpox eradication may pose a higher risk to infection. Recently, several smallpox vaccines have become registered as a vaccine to protect against mpox [Reference Gruber10]. The first documented outbreak of mpox outside of Africa was in the United States of America in 2003 with exposure from prairie dogs, and only several detected events of importations have occurred globally due to travellers arriving from endemic areas and none of them lead to sustained local transmission [4, 11]. The only human-to-human transmission reported outside of Africa was in the United Kingdom (UK) in 2018 [Reference Vaughan12].
Considering the global travel network, large European cities had a high risk of importing mpox [Reference Au13]. The current multi-country outbreak in 2022 was first identified in the UK, and sustained local transmission has been mainly observed in Europe and the Americas [2]. Moreover, the disease has been continuously identified in a majority of global locations. The first case was detected on 6 May 2022 in the UK due to importation from Nigeria [2, Reference Vivancos14]. While the index case still remain unclear, intra- and international spread of the disease has been observed with evidence of sustained human to human transmission [Reference Vivancos14, Reference Perez Duque15]. As of 4 September, countries which have reported a high cumulative number of cases (>3000) globally were the United States of America (n = 19 351), Spain (n = 6645), Brazil (n = 5197), France (n = 4646), Germany (n = 3493) and the United Kingdom (n = 3413) [1]. Outside of African region, eight deaths have been confirmed to present [1]. A unique characteristic of the current spread of mpox cases is that most cases are concentrated among young men, in the population of men who have sex with men (MSM) [1, Reference Vaughan12, Reference Perez Duque15, Reference Ferraro16]. Typically mpox is not considered to be a sexually transmitted infection, while it can be transmitted easily during sexual and intimate contact [Reference Guarner, del Rio and Malani17]. While global international travel volume has been largely reduced from 2020–2021, in the present year, the International Air Transport Association expects air passenger volume (PV) to be 69% compared to 2019 (pre-COVID-19 pandemic) [18]. Due to resumptions of human movement via airline transportation, travellers could unintentionally cross the border with mpox infection.
Several mathematical modelling techniques have been developed responding to the rapid dissemination of emerging infectious diseases fuelled by airline travel network [Reference Colizza19–Reference Tatem, Rogers and Hay24]. Practically travel restrictions have been put in place in several boarders during the COVID-19 pandemic, specifically when it was discovered in Wuhan, China and also when a new variant of concern has been identified (i.e. the Omicron variant in South Africa) [Reference Grépin25–Reference Bai27]. A recent study estimated the undetected importation risk against the Omicron variant among low and middle income countries due to limited surveillance capabilities [Reference Bi28]. Quantifications of the impact of travel restriction against the risk of importation has been simulated using airline transportation network arriving from Wuhan, China [Reference Shi29]. Several studies have also quantified the delayed epidemic progression given the stringent travel restriction in Wuhan, China [Reference Chinazzi30, Reference Anzai31].
The present study modified the model previously applied against COVID-19 for the quantification of risk of importation [Reference Shi29]. Our study aimed to quantify the global risk of importation using airline transportation data. Using a hazard-based model and the concept of effective distance based on travel network data, we explored patterns of domestic and international population movement. Our findings on travel patterns could contribute to inform public health interventions, especially for understanding the risk of observing an emerging disease across the border.
Methods
Dataset and global airline network
The dates of first onset of mpox case for each location (including country, city and/or name of hospital) were extracted from open-access database developed in response to the multi-country outbreak [Reference Kraemer32, 33] at 5 September 2022. The data included 175 countries or territories. Two authors, RK and DY, independently checked the validity of data against official announcements from WHO and each governmental report. The extracted case information was then matched with the airport information based on the nearest neighbourhood approach. To construct the airline transportation network, we used the ADS-B exchange data [34]. All flights included in the ADS-B exchange data within a single day of 1 December 2019 (before the COVID-19 pandemic) was extracted. The dataset provides a graph of global travel information consisting of 1724 nodes (corresponds to each airport) and 21 704 edges with edge-weights (corresponds to direct flights between two airports with its PV. The PV on a certain flight was estimated as the reported (maximum) number of seats of the airplane. Then, the PV was multiplied by 0.93 for domestic travel and 0.69 for international travel [18].
Effective distance
To model the impact of airline network on mpox transmission, an idea of effective distance, which was introduced by Brockmann and Helbing [Reference Dirk and Dirk35] and frequently used in previous studies for forecasting the global spread of emerging infectious disease such as SARS, influenza H1N1-2009, MERS and COVID-19 [Reference Otsuki and Nishiura22, Reference Shi29], was estimated from the airline network. The effective distance is defined from the minimum distance on the adjacency matrix of the network, incorporating the PV-weighted path length and the degree of each node. In other words, the effective distance is a metric quantifying the network distance between each nodes with the weighted edge being proportional to the PV, irrespective of the physical distance between locations.
The effective distance, d ij, between London Heathrow airport (ICAO code: EGLL) and the ith airport in the jth country is defined as the minimum length among all possible effective paths. The effective paths from Heathrow airport to the ith airport with a sequence of l transit airports {a Heathrow, a 1, …, a l−1, a i} is given by
where P l,m denotes the transition probability matrix from the lth to the mth airport. Each element in P l,m is estimated by $P_{l, m} = \left({w_{lm}/\left({\mathop \sum \nolimits_n w_{ln}} \right)} \right), \;$ where w lm is the PV that moved from the lth to the mth airport. Lastly, d ij is defined as the minimum effective paths, which is given by
As we will discuss in the next section, since the network structure and its associated effective distance changed after the travel restrictions due to the change in the PV, the effective distance d ij is dynamically changed in the assumed three scenarios described below.
Modelling with effective distance: hazard-based approach
We modelled the risk of importing mpox by estimating the survival probability in each country. Let T be a random variable indicating the survival time in each airport from the first case in the UK (6 May 2022) to importation at the airport. Also define the survival probability at time of t as F(t) = P(T > t) with the probability density function (pdf) of f(t) = −dF(t)/dt. t indicates day, and t = 0 is 6 May 2022. The associated hazard function at time of t for importation of mpox from the UK for the ith airport in the jth country is modelled in the form of Weibull regression model, which is given by
where p > 0, α > 0, γ is a vector of regression parameters, β is also a regression parameter of interest to measure the impact of the effective distance, f() is a penalised smoothing spline function with the degree of freedom of 4, and Xj is a covariate vector. By using the parameter, p, in Equation (3), the Weibull distribution can flexibly model the survival probability even when it is non-convex shape. In addition, other distributions including log-normal and log-logistic distributions were compared and we confirmed that the Weibull distribution can provide the best performance in terms of AIC. This formulation makes the hazard function and the estimated median time of importation be proportional to the effective distance d ij, which is consistent with Shi et al. (2021) and Otsuki and Nishiura (2016) [Reference Otsuki and Nishiura22, Reference Shi29]. The covariates Xj include: income per capita at 2022 [36], the proportion of working age at 2020 [37], the proportion of sexual minorities concealing their sexual orientation [Reference Pachankis and Bränström38], the proportion of MSM population [39, 40], Socio Demographic Index at 2019 [36] and WHO region (i.e. African Region (AFR), Eastern Mediterranean Region (EMR), European Region (EUR), Region of the Americas (AMR), South-East Asian Region (SEAR), Western Pacific Region (WPR)). Complete case analysis was considered, and thus airports with incomplete covariate information were excluded from the estimation.
The parameters were estimated by the maximum likelihood approach. Then, the future hazard function at 31 December 2022, was predicted by extrapolating the time variable t. In order to capture the importation risk from the UK, the following countries currently designated as endemic of mpox is not included in the parameter estimation: Benin, Cameroon, the Central African Republic, the Democratic Republic of the Congo, Gabon, Ghana, Ivory Coast, Liberia, Nigeria, the Republic of the Congo, Sierra Leone and South Sudan [2]. Further, to check the goodness-of-fitting in the model, we calculated the concordance index, which measures the agreement between an observed response and the predictor.
Lastly, we conducted the sensitivity analysis by weakening the assumption in the effective distance: i.e. since the effective distance strongly depends on the assumption that mpox cases has been spreading from the UK, we checked how our result would be changed when weakening this assumption (i.e. not specifying the starting point of the virus spread). More precisely, we used a ‘closeness centrality index’ on the airline network, which measures how attractive a certain airport is in the PV sense, instead of the effective distance in the model. The closeness centrality for the ith airport is defined as
where w ji is the PV that moved from the jth to the ith airport and S i is the set of airports that are connected to the ith airport. Then, instead of d ij in Equation (3), C i is used. C i does not assume the starting point of the virus spread, and in that sense we do not make the assumption that the infection is spreading from the UK in this sensitivity model.
Hypothetical scenarios to estimate relative risk reduction due to travel restriction
To estimate the impact of travel restrictions on the importation risk, we calculated the (observed) cumulative risk at time of t, defined by
Then we compared $R_{ij}^{{\rm obs}} ( t )$ with the cumulative risk of following hypothetical scenarios: (H1) Reduce the current PV from/to infected countries by 50%, (H2) Increase the current PV to ‘pre-COVID-19 level in 2019’ (cf. the current PV was assumed 93% for domestic and 69% for international travel, respectively, compared with the pre-COVID-19 level) [18], and further reduce the PV from/to infected countries by 90%, and (H3) Reduce the current PV to ‘the level at the most severe travel restrictions in 2021’ (i.e. the PV is assumed 61% for domestic and 27% for international travel, respectively, compared with compared with the pre-COVID-19 level), and further reduce the PV from/to infected countries by 50% [18]. Once the regression parameters in Equation (3) was estimated, the cumulative risks based on these scenarios can be calculated by plugging the scenario-specific d ij into Equation (3): i.e. in a similar way with the calculation of $R_{ij}^O$, the cumulative risks in (H1)–(H3) are given by
where h = 1, 2, 3 indicates scenarios (H1)–(H3), respectively, and $d_{ij}^h$ is the effective distance based on each scenario assumption. Lastly, we estimated the relative risk change as follow:
To measures the proportion of expected risk reduction between observed and the hypothetical scenarios the relative risk change was calculated at t = 239 (31 December 2022).
Results
Figure 1a shows the entire flight network with the associated PV. PV tends to be higher in intercontinental flights compared to intracontinental flights. Figure 1b indicates PV arriving/departing from the UK and Heathrow Airport. A total of 176 countries (and territories), including the UK, and 1680 airports were included in this analysis. The arrival time ranged from 9 to 48 days since the first case was identified in the UK on 6 May 2022.
Figures 2a and b show the estimated and predicted cumulative risk $R_{ij}^O$ at 5 September and 31 December 2022, respectively. The increased risk over time was similar between WHO regions; the median risk ratios (defined as $R_{ij, \;\;{\rm Dec}}^O /R_{ij, \;{\rm Sep}}^O$) and interquartile range (IQR) in AFR, EMR, EUR, AMR, SEAR, and WPR were 1.56 (IQR = 0.0305), 1.57 (IQR = 0.0593), 1.52 (IQR = 0.0860), 1.50 (IQR = 0.0997), 1.58 (IQR = 0.0196) and 1.58 (IQR = 0.0157), respectively. The estimated concordance index was 0.816, which implicates the model has good fitting ability. To check the robustness of our result, we note that similar results were obtained even in the sensitivity analysis (Supplemental Figure).
Figures 3a–c show the estimated relative risk change under the assumption of (H1)–(H3). The mean (Standard deviation (s.d.), max and min) for the relative risk change were 0.968 (s.d. = 0.075, max = 1.195, min = 0.766), 0.953 (s.d. = 0.240, max = 1.982, min = 0.433) and 0.963 (s.d. = 0.113, max = 1.291, min = 0.685) for (H1)–(H3), respectively. Regarding the geographical distribution of the risk change, in (H1), there was characteristic risk decrease, especially in Europe, Scandinavia, Southeast Asia and Australasia, while there was risk increase in Central America and the Caribbean countries. In (H2), where the overall PV is assumed to return to ‘pre-COVID-19 level’, importation risk increase is observed at similar locations as observed in (H1), while the increase was stronger due to increased travel volume. Surprisingly, areas observing risk decrease was also similar to (H1), and the decrease was stronger even despite increased overall PV. In (H3), risk increase is prevented compared to (H2) due to heavy reduction in the PV assuming 2021 level. However, the strong risk decreases as observed in (H2) is not observed even with significant decrease in overall PV. Interestingly, in all intervention scenarios Central America had an increased risk.
Table 1 shows the estimated risk among top five and bottom five country/territory as of 5 September 2022, 31 December 2022, and three hypothetical travel restriction scenarios. High risks were observed in Switzerland, Luxembourg, Iceland, Qatar, and Malta regardless of estimated time and scenarios. Generally, low risks were observed in Samoa, Palau, Syria, Saint Kitts and Nevis, Christmas Island and Tonga. Apparent changes in the estimated risk reflect the strength of connectedness between London, UK. The estimated risk by scenario did not drastically change in the top or bottom five country/territory. Detailed values by countries/territories are provided in the Supplementary Table.
The values shown in parenthesis is the estimated risk. Detailed values of 176 countries/territories are provided in the Supplementary Table.
Discussion
Employing a hazard based model and utilising the idea of effective distance, the present study estimated the importation risk against mpox. Assuming that the current flight volume would be maintained, the risk of importation by 31 December 2022 is expected to be substantial in multiple locations, including areas which yet have experienced sustained local transmission (Fig. 2). Strong risks are seen in locations with large PV with the presence of closely connected flights irrespectively to the actual distance from London, UK. Our result highlights the importance to enhance surveillance against mpox in nations with a high risk of importing mpox.
To confirm a hypothetical scenario where travel restrictions are imposed, we reduced PV from/to countries already detected to have mpox importation. The reduction of PV by 50% may be considered as a situation when travel recommendations were made not to travel in these locations unless necessary (H1 and H3). The reduction of PV by 90% may be considered as a situation when strict travel restrictions were implemented to/from countries identifying mpox (H2). The relative risk reduction given travel restriction only had a minor effect to the risk of importation (Fig. 3a). To verify the sensitivity to different PV on the relative risk reduction, we changed the PV from/to identified location, and the degree of reduction in overall PV considering the travel volume in 2019 (pre-COVID-19 level; high PV) and 2021 (least travel volume during the COVID-19 pandemic; low PV). While minor changes in the risk is observed, varying the global airline PV and travel restrictions from/to identified locations did not strongly contribute to modify the risk of importation (Fig. 3b and c), suggesting that the degree of PV has a nonlinear effect on the risk reduction, and the optimal size of volume reduction may depend on the connectivity between each airport network as also discussed previously [Reference Shi29]. Therefore, our hypothetical scenarios examined that practical implementation of travel restrictions or recommendations to reduce PV in order to minimise the risk of importing mpox cases may not be an efficient strategy. Rather, intensified contact tracing and isolation would be more important once a single case is identified in a new location.
Several limitations must be discussed. First, this study estimated the probability of importation using only airline network data, while sea and ground (automobiles and railway) network are also drivers to human mobility. Second, since we relied on airline transportation data within a single day in 1 December 2019, our analysis could only take into account of the change in the airline travel volume by 2022. Therefore, the changes in network structure due to the COVID-19 pandemic, or by the humanitarian crisis occurring between Ukraine and Russia may not have been adequately addressed, which may result to affect the precision on our estimate. Third, we defined that the spread of mpox originated from London, UK and estimated the global importation risk. However, similar results were obtained in our sensitivity analysis relaxing this assumption. Fourth, our analysis focused on the risk of importation, and therefore the risk of local transmission given importation is not quantified. Despite these limitations, our projection exercise highlights the propagating global risk of importation of mpox cases using airline transportation network.
In conclusion, travel restrictions can impose strong economic and social impact, and thus careful evidence-based decision process is necessary [Reference Meier26]. While our simple model may not fully capture the complex dynamics of global disease transmission, our simulation showed that in the case of mpox, airline travel restrictions may not be the practical intervention to prevent importation in most areas. Instead of preventing the importation of mpox cases via airline networks, countries especially considered to have a high risk of importation should enhance local capacities for the identification of mpox and prepare to carry out contact tracing and isolation.
Supplementary material
The supplementary material for this article can be found at https://doi.org/10.1017/S0950268823000456.
Author contributions
RK and DY led the study. All authors took responsibility for the integrity of the data and the accuracy of the data analysis. All the authors made critical revisions to the manuscript for important intellectual content and gave final approval of the manuscript. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding bodies.
Financial support
This work was supported by JST, PRESTO Grant Number JPMJPR21RC, Japan (DY), JSPS KAKENHI Grant Number 21K17307 (RK), and MHLW Research on Emerging and Re-emerging Infectious Diseases and Immunization Program Grant Number JPMH20HA2007 and JPMH21HA2008 (MS).
Conflict of interest
The authors have declared no conflicts of interest.
Data availability statements
The data underlying this article and R programs will be shared on reasonable request to the corresponding author.